[1]KOTZLER MP，BLANK S，BANTLEON FI，et al．Donor substratebinding and enzymatic mechanism of human core al，6-fuco-syltransferase(FIIT8)［J］.Biochim Biophys Aeta，2012，1820(12)：1915-1925．
[2]DHANISHA SS,GURUVAYOORAPPAN C，DRISHYA S，et al.Mucins:Structural diversity,biosynthesis,its role in pathogenesis and as possible therapeutic targets［J］.Crit Rev Oncol Hematol,2018,122:98-122.
[3]CALVO MB,FIGUEROA A,PULIDO EG，et al.Potential role of sugar transporters in cancer and their relationship with anticancer therapy［J］.Int J Endocrinol,2010,2010:2033.
[4]MITA Y,AOYAGI Y,SUDA T，et al.Plasma fucosyltransferase activity in patients with hepatocellular carcinoma,with special reference to correlation with fucosylated species of alpha-fetoprotein［J］.J Hepatol,2000,32:946-954.
[5]YU HJ，SHU J,LI Z.Lectin microarrays for glycoproteomics:an overview of their use and potential［J］.Expert Rev Proteomics,2020,17:27-39.
[6]SILSIRIVANIT A.Glycosylation markers in cancer［J］.Adv Clin Chem,2019,89:189-213.
[7]YATES B,BRASCHI B,GRAY KA，et al.Genenames org:the HGNC and VGNC resources in 2017［J］.Nucleic Acids Res,2017,45:D619-D625.
[8]KANG XN,WANG N,PEI C，et al.Glycan-related gene expression signatures in human metastatic hepatocellular carcinoma cells［J］.Exp Ther Med,2012,3:415-422.
[9]COOPER J,GIANCOTTI FG.Integrinsignaling in cancer:mechanotransduction,stemness,epithelial plasticity,and therapeutic resistance［J］.Cancer Cell,2019,35:347-367.
[10]CHANDLER KB,COSTELLO CE,RAHIMI N.Glycosylation in the tumor microenvironment:implications for tumor angiogenesis and metastasis［J］.Cells,2019,8(6):544.
[11]VAJARIA BN,PATEL PS.Glycosylation:a hallmark of cancer［J］.Glycoconj J,2017,34:147-156.
[12]SRIDEVI U,JAIN A,NAGALAXMI V，et al.Expression of E-cadherin in normal oral mucosa,in oral precancerous lesions and in oral carcinomas［J］.Eur J Dent,2015,9:364-372.
[13]ZHENG WY,ZHANG DT,YANG SY，et al.Elevated matrix metalloproteinase-9 expression correlates with advanced stages of oral cancer and is linked to poor clinical outcomes［J］.J Oral Maxillofac Surg,2015,73:2334-2342.
[14]GHALLAB NA,SHAKER OG.Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions［J］.Clin Oral Investig,2017,21(3):937-947.
[15]LAUBLI H,BORSIG L.Alteredcell adhesion and glycosylation promote cancer immune suppression and metastasis［J］.Front Immunol,2019,10:2120.
[16]XIAO H,WOODS EC,VUKOJICIC P,et al.Precision glycocalyx editing as a strategy for cancer immunotherapy［J］.Proc Natl Acad Sci USA,2016,113:10304-10309.
[17]NAKAGAWA H,FUJITA M,FUJIMOTO A.Genome sequencing analysis of liver cancer for precision medicine［J］.Semin Cancer Biol,2019,55:120-127.
[18]WANG YQ,FUKUDA T,ISAJI T,et al.Loss of α1,6-fucosyltransferase inhibits chemical-induced hepatocellular carcinoma and tumorigenesis by down-regulating several cell signaling pathways［J］.FASEB J,2015,29:3217-3127.
[19]LI S,LIU XY,PAN Q，et al.Hepatitis C virus-induced FUT8 causes 5-FU drug resistance in human hepatoma Huh7.5.1 cells［J］.Viruses,2019,11(4):378.
[20]HUANG H,LIU YB,YU PS，et al.MiR-23a transcriptional activated by Runx2 increases metastatic potential of mouse hepatoma cell via directly targeting Mgat3［J］.Sci Rep,2018,8:7366.
[21]LU JS,ISAJI T,IM S，et al.Expression of N-acetylglucosaminyl-transferase Ⅲ suppresses α2,3-sialylation,and its distinctive functions in cell migration are attributed to α2,6-sialylation levels［J］.J Biol Chem,2016,291:5708-5720.
[22]LIU J,LIU HO,ZHANG WJ，et al.N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation［J］.Glycobiology,2013,23:1097-1109.
[23]WU Q,LIU HO,LIU YD，et al.Decreased expression of hepatocyte nuclear factor4α(Hnf4α)/microRNA-122(miR-122)axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity［J］.J Biol Chem,2015,290:1170-1185.
[24]ZHANG GD,LU JQ,YANG M，et al.Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer［J］.Cancer Immunol Immunother,2020,69:175-187.
[25]FERNANDEZ L,VARGAS T，et al.The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance［J］.Sci Rep,2018,8:8485.
[26]ALLAM H,JOHNSON BP,ZHANG M，et al.The glycosyltransferase GnT-Ⅲ activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer［J］.J Biol Chem,2017,292:16351-16359.
[27]HO WL,CHOU CH,JENG YM，et al.GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma［J］.Oncotarget,2014,5:12247-12259.
[28]SWEENEY JG,LIANG J,ANTONOPOULOS A，et al.Loss of GCNT2/I-branched glycans enhances melanoma growth and survival［J］.Nat Commun,2018,9:3368.
[29]SUMARDIKA IW,YOUYI C,KONDO E，et al.Oβ-1,3-galactosyl-glycosyl-glycoprotein β-1,6-acetyl glucosaminyl transferase 3 increases MCAM stability,which enhances S100A8/A9-Mediated cancer motility［J］.Oncol Res,2018,26:431-444.
[30]THOMA SZ,MELVI NR,PRESTON DS，et al.Development and validation of a universal high-throughput udp-glycosyltransferase assay with a time-resolved fret signal［J］.Assay Drug Dev Technol,2016,14:240-251.
[31]ANUMULA KR.Activity determination of glycosyl transferases［J］.Methods Mol Biol,2019,1934:83-92.
[32]NGO M,MICHAEL DL.Methods for determining glycosyltransferase kinetics［J］.Methods Mol Biol,2017,1588:59-70.
[33]RILLAHAN CD,ANTONOPOULOS A,LEFORT CT，et al.Global metabolic inhibitors of sialyl-and fucosyltransferases remodel the glycome［J］.Nat Chem Biol,2012,8:661-668.
[34]CINZIA B,UGO S,FRANCESCO P，et al.Effects of microRNAs on fucosyltransferase 8(FUT8)expression in hepatocarcinoma cells［J］.PLoS One,2013,8:e76540.